

P&T Motion History Targeted Immune Modulators (TIMs)

| Drugs reviewed | Motion | Date reviewed | Surveillance accepted as adequate | Reiteration of prior motion | Decision |
|--|---|----------------|-----------------------------------|-----------------------------|------------------|
| abatacept adalimumab anakinra apremilast baricitinib brodalumab certolizumab pegol etanercept golimumab guselkumab infliximab ixekizumab natalizumab risankizumab rituximab sarilumab secukinumab tildrakizumab tocilizumab tofacitinib upadacitinib ustekinumab vedolizumab | <p>TIMs for Plaque Psoriasis and Psoriatic Arthritis and Rheumatoid Arthritis and Ankylosing Spondylitis</p> <p>After considering the evidence of safety, efficacy, effectiveness and special populations for the use of targeted immune modulators for their FDA approved indications relative to rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis, I move that: baricitinib, guselkumab, risankizumab, tildrakizumab, upadacitinib, abatacept, adalimumab, anakinra, apremilast, brodalumab, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, rituximab, sarilumab, secukinumab, tocilizumab, tofacitinib, and ustekinumab are efficacious. The PDL must include a drug approved for treatment of the following FDA indications (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis) and must include a self-administered agent if indicated.</p> <p>These medications cannot be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Motion: Park 2nd: Beste</p> | June 15, 2022 | NA | No | Passed unanimous |
| abatacept adalimumab anakinra | After considering the evidence of safety, efficacy, effectiveness and special populations for the use of targeted immune modulators for their FDA approved | April 21, 2021 | Yes Park Lee | Yes Flatebo Brown | Passed unanimous |

Bold = new this update
 Grey= not reviewed
 6/16/2022

P&T Motion History Targeted Immune Modulators (TIMs)

| | | | | | |
|---|---|--|--|--|--|
| apremilast baricitinib brodalumab certolizumab pegol etanercept golimumab guselkumab infliximab ixekizumab natalizumab risankizumab rituximab sarilumab secukinumab tildrakizumab tocilizumab tofacitinib upadacitinib ustekinumab vedolizumab | indications, I move that: baricitinib, guselkumab, risankizumab, tildrakizumab, upadacitinib, abatacept, adalimumab, anakinra, apremilast, brodalumab, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, natalizumab, rituximab, sarilumab, secukinumab, tocilizumab, tofacitinib, ustekinumab, vedolizumab are efficacious. The PDL must include a drug approved for treatment of the following FDA indications (rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis) and must include a self-administered agent if indicated. These medications cannot be subject to therapeutic interchange in the Washington preferred drug list. Motion: Park 2 nd : Storhaug | | | | |
|---|---|--|--|--|--|